Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$6.00 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.98 -0.02 (-0.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OTLK 6.00 0.00(0.00%)
Will OTLK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OTLK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OTLK
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
OTLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
Other News for OTLK
JMP Securities healthcare analysts hold an analyst/industry conference call
Outlook Therapeutics? to Participate in the Virtual Investor Closing Bell Series
Outlook Therapeutics? Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
JMP Securities healthcare analysts hold an analyst/industry conference call
Buy Rating Affirmed for Outlook Therapeutics Amid Strong Market Potential and Upcoming Milestones for ONS-5010/Lytenava